GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Appointment of as Other of the company w.e.f. April 20, 2026.
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
GlaxoSmithKline Pharmaceuticals has announced the appointment of Mr. Vinay Subramanian as Commercial Head – Oncology, effective 20th April 2026. He will be part of the company's leadership team and Senior Managerial Personnel based in Mumbai. Vinay brings over 24 years of experience across Pharmaceuticals, Life Sciences, Healthcare Devices, and Medical Technology sectors. Prior to joining GSK, he served as India Enabling Leader at Roche Products India, managing the immunotherapy portfolio. His previous roles include leadership positions at GE Healthcare, Becton Dickinson & Company, and Pfizer, with a track record in sales, business development, and key account management. He holds an MBA from Annamalai University and executive program credentials from UC Berkeley-Haas and GE Crotonville Leadership Academy.
This appointment strengthens GSK's oncology leadership with an experienced executive from a competitor (Roche), which could support the company's oncology business growth. As this is a senior management addition rather than a C-suite or board-level change, the market impact is likely neutral to mildly positive.